AudioScholar Hematology Weekly

AudioScholar
  • 0.0 (0)
  • Medicine
  • Updated Weekly

Hematology — a weekly podcast briefing of the most significant peer-reviewed hematology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

  1. Aug 12

    This Week in Hematology — Aug 12, 2026

    Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning thrombosis risk stratification and antibody-mediated clotting, long-term outcomes in lymphoma and myeloma immunotherapy, and the diagnosis and management of under… This week's papers: 1. Risk of recurrence in patients with provoked venous thromboembolism: a prospective cohort study. — Blood 2026 2. Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. — Blood 2026 3. How I treat bleeding in women and girls with hemophilia/hemophilia carriers. — Blood 2026 4. Long-term follow-up of PET/CT-adapted therapy after three cycles of ABVD for all stages of classic Hodgkin lymphoma: Results of the GATLA LH-05 trial. — British Journal of Haematology 2026 5. Decade-long persistence of CD19 CAR T cells in B cell lymphomas. — Nature Medicine 2026 6. How I treat autoimmune neutropenia in adults. — Blood 2026 7. Monoclonal Gammopathy of Thrombotic Significance. — American Journal of Hematology 2026 8. A quantitative definition of the clinical manifestations of GATA2 deficiency in adults. — Blood 2026 9. Association between Pulmonary Vascular Obstruction Phenotype and Pulmonary Embolism Recurrence: Results from the PADIS-PE Study. — Thrombosis and Haemostasis 2026 10. Prevalence and thrombotic risk of PF4-dependent platelet-activating antibodies. — Journal of Thrombosis and Haemostasis 2026 Listen at https://audioscholar.cc/episode/m8h7qr3e5t

  2. Aug 6

    This Week in Hematology — Aug 5, 2026

    Welcome to This Week in Hematology. This week we're covering nine notable papers spanning myeloma therapeutics and supportive care, the myeloproliferative neoplasms, and a cluster of bleeding-and-clotting papers with immediate bedside relevance, plus… This week's papers: 1. Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200 — Blood Advances 2026 2. Systemic Bevacizumab for Severe Bleeding From Acquired Gastrointestinal Vascular Malformations — American Journal of Hematology 2026 3. High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients — British Journal of Haematology 2026 4. Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era — British Journal of Haematology 2026 5. Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia — Journal of Thrombosis and Haemostasis 2026 6. Identification of Clinical Sub-Phenotypes of Sickle Cell Disease Using Latent Class Analysis — American Journal of Hematology 2026 7. Classic Hodgkin Lymphoma: A Review — JAMA 2026 8. In a nutshell review of hereditary antithrombin deficiency in pregnancy — British Journal of Haematology 2026 9. Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis — Leukemia 2026 Listen at https://audioscholar.cc/episode/4shw556chb

  3. Jul 31

    This Week in Hematology — Jul 31, 2026

    Welcome to This Week in Hematology. This week we're covering 9 notable papers spanning advances in myeloid neoplasms and clonal hematopoiesis, optimization of frontline lymphoma and leukemia therapies, and new insights into managing cellular therapy… This week's papers: 1. Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826) — Blood Advances 2026 2. Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms — Blood 2026 3. Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML — Blood Advances 2026 4. Robust CD4CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma — Science Translational Medicine 2026 5. Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome — Blood Advances 2026 6. Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia — Blood Advances 2026 7. Real-world investigation of germline predisposition to myelodysplastic syndromes — Blood Advances 2026 8. Characteristics of Donor and Recipient Clonal Hematopoiesis in Nonmyeloablative Transplant for Sickle Cell Disease — Blood 2026 9. Long-term efficacy and safety of romiplostim plus immunosuppressive therapy as first-line treatment in patients with aplastic anaemia: 2-year interim analysis… — British Journal of Haematology 2026 Listen at https://audioscholar.cc/episode/7h5c4kz54s

  4. Jul 22

    This Week in Hematology — Jul 22, 2026

    Welcome to This Week in Hematology. This week we're covering 8 notable papers spanning severe aplastic anemia management, acute myeloid leukemia prognostication and measurable residual disease, and plasma cell dyscrasias. Let's dive in. In the realm… This week's papers: 1. Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superi… — American journal of hematology 2026 2. Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry. — Leukemia 2026 3. Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma. — Blood cancer journal 2026 4. Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced-Stage Extra-Nodal NK/T-Cell Lymphoma: A Multicenter Retrospective Study. — American journal of hematology 2026 5. Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy. — American journal of hematology 2026 6. Efficacy and Safety of BCMA-Targeted Therapies in Relapsed or Refractory AL Amyloidosis: A Descriptive Pooled Analysis. — Blood advances 2026 7. Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre… — British journal of haematology 2026 8. A Prospective Study of Familial Predisposition in Plasma Cell Dyscrasias. — Blood advances 2026 Listen at https://audioscholar.cc/episode/vya8j279qg

  5. Jul 15

    This Week in Hematology — Jul 15, 2026

    Welcome to This Week in Hematology. This week we are covering ten notable papers spanning clinical advances in malignant hematology, evolving strategies in non-malignant disorders like hemophilia and sickle cell disease, and critical safety insights… This week's papers: 1. Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or othe… — Leukemia 2026 2. Recurrent VTE in patients with thrombophilia after stopping anticoagulation - A systematic review and meta-analysis — Blood Advances 2026 3. Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis — Blood Cancer Journal 2026 4. Unmet needs despite standard-of-care prophylaxis in Hemophilia A: improved outcomes after switching to Efanesoctocog Alfa — Blood Advances 2026 5. FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs with severe hemophilia A on emicizumab prophylaxis: real world data from the P… — Journal of Thrombosis and Haemostasis 2026 6. Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study — British Journal of Haematology 2026 7. Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS Trial — Blood Advances 2026 8. Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia — Leukemia 2026 9. Seroprotection after Measles Vaccination in Children with Sickle Cell Anemia Receiving Hydroxyurea — Blood Advances 2026 10. Blood Rheology After Allogeneic Hematopoietic Stem Cell Transplantation or Gene Therapy in Sickle Cell Disease — Blood Advances 2026 Listen at https://audioscholar.cc/episode/943fmhzbxs

  6. Jul 8

    This Week in Hematology — Jul 8, 2026

    Welcome to This Week in Hematology. This week we are covering eight notable papers spanning advances in cellular immunotherapies, optimization of plasma cell disorder regimens, and novel risk stratification and supportive care strategies in hematolog… This week's papers: 1. Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm. — Blood 2026 2. Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma. — Blood 2026 3. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem c… — British Journal of Haematology 2026 4. How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists. — Blood 2026 5. High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone >= 1. — American Journal of Hematology 2026 6. Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies. — Blood Cancer Journal 2026 7. POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management. — American Journal of Hematology 2026 8. Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell ly… — British Journal of Haematology 2026 Listen at https://audioscholar.cc/episode/kfhpqpjq3z

  7. Jul 1

    This Week in Hematology — Jul 1, 2026

    Welcome to This Week in Hematology. This week we are covering ten notable papers spanning three major areas: myeloid malignancies including myelofibrosis, myelodysplastic syndromes, and acute myeloid leukemia; lymphoid neoplasms featuring chronic lym… This week's papers: 1. TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. — Blood 2026 2. Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International C… — Blood Cancer Journal 2026 3. Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia. — Blood Cancer Journal 2026 4. Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs. — Blood Advances 2026 5. Diagnosis and management of neutropenia in adults: Expert guidance. — British Journal of Haematology 2026 6. Venous Thromboembolism in Women on Estrogen Therapy: Presentation, Management, and Outcomes in the RIETE registry. — Blood Advances 2026 7. One-stage Assay Factor VIII Activity Reflects AAV-Derived Factor VIII-Enhanced Thrombin Activation and Predicts Phenotype. — Blood 2026 8. Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial. — American Journal of Hematology 2026 9. Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma. — Blood Advances 2026 10. Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers. — Blood Cancer Journal 2026 Listen at https://audioscholar.cc/episode/9p9gqh4bza

  8. Jun 25

    This Week in Hematology — Jun 24, 2026

    Welcome to This Week in Hematology. This week we are covering nine notable papers spanning advanced cellular therapies and precision monitoring in lymphomas, optimized treatment protocols in chronic lymphocytic leukemia and hemophilia, and novel syst… This week's papers: 1. Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma. — Blood cancer journal 2026 2. Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, random… — Lancet (London, England) 2026 3. Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a rand… — Lancet (London, England) 2026 4. Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study. — Blood advances 2026 5. Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma. — Blood advances 2026 6. Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis. — Blood advances 2026 7. Prevention and Treatment of Peanut Allergy. — The New England journal of medicine 2026 8. Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. — The New England journal of medicine 2026 9. SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL. — Blood advances 2026 Listen at https://audioscholar.cc/episode/k89a6bm77z

See All (15)

About

Hematology — a weekly podcast briefing of the most significant peer-reviewed hematology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

Information